Home » Stocks » CBAY

CymaBay Therapeutics Inc. (CBAY)

Stock Price: $3.94 USD -0.23 (-5.52%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $3.90 -0.04 (-1.02%) May 11, 5:43 AM
Market Cap 271.66M
Revenue (ttm) n/a
Net Income (ttm) -50.99M
Shares Out 68.89M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $3.94
Previous Close $4.17
Change ($) -0.23
Change (%) -5.52%
Day's Open 4.14
Day's Range 3.92 - 4.13
Day's Volume 1,157,395
52-Week Range 3.16 - 9.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

1 month ago - GlobeNewsWire

Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC):

1 month ago - GlobeNewsWire

NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

1 month ago - GlobeNewsWire

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: EDIT, MRNS, NTLA, VRTX
4 months ago - Zacks Investment Research

NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...

5 months ago - GlobeNewsWire

NEWARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

5 months ago - GlobeNewsWire

The FDA lifted all holds on all CymaBay liver disease studies back in July, since, shares have begun clawing back, +319% upside YTD. The company has presented positive top-line data from the ENHANCE stu...

6 months ago - Seeking Alpha

CymaBay Therapeutics (CBAY) CEO Sujal Shah on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase secr...

6 months ago - GlobeNewsWire

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

6 months ago - GlobeNewsWire

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

NEWARK, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients...

8 months ago - GlobeNewsWire

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: APTX, EOLS, IBIO, SIEN
8 months ago - 24/7 Wall Street

CymaBay Therapeutics, Inc.'s (CBAY) CEO Sujal Shah on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise...

9 months ago - GlobeNewsWire

CymaBay Therapeutics Inc. (NASDAQ: CBAY) posted a huge gain to start the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangitis (PBC).

9 months ago - 24/7 Wall Street

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC 

9 months ago - GlobeNewsWire

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC

10 months ago - GlobeNewsWire

Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.

11 months ago - The Motley Fool

CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders CymaBay Therapeutics, Inc. Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

11 months ago - GlobeNewsWire

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Other stocks mentioned: ALRN, EFOI, MRSN, MVIS
11 months ago - Zacks Investment Research

A do-over on one of its drugs is a potential game-changer for CymaBay.

11 months ago - The Motley Fool

CymaBay Therapeutics (CBAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge.

Other stocks mentioned: GNFT
11 months ago - Benzinga

CymaBay Therapeutics Inc. (NASDAQ: CBAY) shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.

11 months ago - 24/7 Wall Street

Shares of CymaBay Therapeutics Inc. CBAY, +123.91% rocketed on in very active morning trading Tuesday, after an upbeat report on results of a study of its treatment of liver disease prompted a wave of u...

11 months ago - Market Watch

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, BHVN, MRNS, PTCT, SLDB, TBIO
1 year ago - InvestorPlace

CymaBay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

NEWARK, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise...

1 year ago - GlobeNewsWire

CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Other stocks mentioned: AGN, CNAT, GLMD, ICPT, MDGL
1 year ago - Zacks Investment Research

Even in a winning market, these stocks fell. Find out why.

Other stocks mentioned: ACB, KL
1 year ago - The Motley Fool

The company has halted the development of its lead drug candidate in one indication and terminated two other studies involving the compound.

1 year ago - The Motley Fool

CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are losing more than 75% of their value Monday after the company said it's halting the development of its lead drug, seladelpar.

1 year ago - Benzinga

Shares of CymaBay Therapeutics Inc. CBAY, +6.12% are down 11% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar.

1 year ago - Market Watch

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

Other stocks mentioned: ASMB, MDGL
1 year ago - The Motley Fool

NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapi...

1 year ago - GlobeNewsWire

NEWARK, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment of primary...

1 year ago - GlobeNewsWire

NEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therap...

1 year ago - GlobeNewsWire

NEWARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therap...

1 year ago - GlobeNewsWire

Primary Sclerosing Cholangitis is an orphan disease with no FDA approved therapeutic options or viable alternatives except surgical interventions.

1 year ago - Seeking Alpha

Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Seladelpar is a specific, new generation PPAR-δ agonist in mid-late phase clinical development for NASH and cholestatic liver diseases, PBC and PSC.

1 year ago - Seeking Alpha

CymaBay Therapeutics tumbled on reporting 12-week data from its phase 2b study using seladelpar to treat patients with nonalcoholic steatohepatitis.

1 year ago - Seeking Alpha

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: BBCP, CVEO, ECA, TIVO
1 year ago - 24/7 Wall Street

About CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia... [Read more...]

Industry
Biotechnology
CEO
Sujal Shah
Employees
41
Stock Exchange
NASDAQ
Ticker Symbol
CBAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is 12.00, which is an increase of 204.57% from the latest price.

Price Target
$12.00
(204.57% upside)
Analyst Consensus: Strong Buy